Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure
- PMID: 19477358
- DOI: 10.1016/j.jacc.2009.02.038
Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure
Abstract
Objectives: We investigated the functional relationship between natriuretic peptides and adiponectin by performing both experimental and clinical studies.
Background: Natriuretic peptides are promising candidates for the treatment of congestive heart failure (CHF) because of their wide range of beneficial effects on the cardiovascular system. Adiponectin is a cytokine derived from adipose tissue with various cardiovascular-protective effects that has been reported to show a positive association with plasma brain natriuretic peptide (BNP) levels in patients with heart failure.
Methods: The expression of adiponectin messenger ribonucleic acid (mRNA) and its secretion were examined after atrial natriuretic peptide (ANP) or BNP was added to primary cultures of human adipocytes in the presence or absence of HS142-1 (a functional type A guanylyl cyclase receptor antagonist). Changes of the plasma adiponectin level were determined in 30 patients with CHF who were randomized to receive intravenous ANP (0.025 microg/kg/min human ANP for 3 days, n = 15) or saline (n = 15).
Results: Both ANP and BNP dose-dependently enhanced the expression of adiponectin mRNA and its secretion, whereas such enhancement was inhibited by pre-treatment with HS142-1. The plasma adiponectin level was increased at 4 days after administration of human ANP compared with the baseline value (from 6.56 +/- 0.40 microg/ml to 7.34 +/- 0.47 microg/ml, p < 0.05), whereas there was no change of adiponectin in the saline group (from 6.53 +/- 0.57 microg/ml to 6.55 +/- 0.56 microg/ml).
Conclusions: Natriuretic peptides enhance adiponectin production by human adipocytes in vitro and even in patients with CHF, which might have a beneficial effect on cardiomyocytes in patients receiving recombinant natriuretic peptide therapy for heart failure.
Comment in
-
A new role for the natriuretic peptides: metabolic regulators of the adipocyte.J Am Coll Cardiol. 2009 Jun 2;53(22):2078-9. doi: 10.1016/j.jacc.2009.02.037. J Am Coll Cardiol. 2009. PMID: 19477359 Free PMC article. No abstract available.
Similar articles
-
Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure.Cardiovasc Res. 2004 Nov 1;64(2):308-14. doi: 10.1016/j.cardiores.2004.07.004. Cardiovasc Res. 2004. PMID: 15485690
-
Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.Pharmacol Ther. 2004 Jun;102(3):223-41. doi: 10.1016/j.pharmthera.2004.04.004. Pharmacol Ther. 2004. PMID: 15246247 Review.
-
Prognostic value of cardiac troponin T in patients with both acute and chronic stable congestive heart failure: comparison with atrial natriuretic peptide, brain natriuretic peptide and plasma norepinephrine.Clin Chim Acta. 2005 Feb;352(1-2):143-53. doi: 10.1016/j.cccn.2004.09.009. Clin Chim Acta. 2005. PMID: 15653109
-
Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure.Int J Cardiol. 2004 Feb;93(2-3):121-30. doi: 10.1016/S0167-5273(03)00156-6. Int J Cardiol. 2004. PMID: 14975537
-
Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer?Clin Exp Pharmacol Physiol. 2006 Mar;33(3):169-76. doi: 10.1111/j.1440-1681.2006.04344.x. Clin Exp Pharmacol Physiol. 2006. PMID: 16487258 Review.
Cited by
-
Sarcopenia is linked to higher levels of B-type natriuretic peptide and its N-terminal fragment in heart failure: a systematic review and meta-analysis.Eur Geriatr Med. 2024 Mar 8. doi: 10.1007/s41999-024-00950-x. Online ahead of print. Eur Geriatr Med. 2024. PMID: 38457043 Review.
-
Assessment of biomarkers and clinical parameters as predictors of survival in patients with chagasic heart failure.PLoS Negl Trop Dis. 2023 Dec 18;17(12):e0011847. doi: 10.1371/journal.pntd.0011847. eCollection 2023 Dec. PLoS Negl Trop Dis. 2023. PMID: 38109427 Free PMC article.
-
Exploring the Mechanistic Link Between Obesity and Heart Failure.Curr Diab Rep. 2023 Dec;23(12):347-360. doi: 10.1007/s11892-023-01526-y. Epub 2023 Dec 15. Curr Diab Rep. 2023. PMID: 38100052 Review.
-
The Interplay between Adipose Tissue Properties and Levels of NT-proBNP in People with HIV.J Obes. 2023 Nov 4;2023:6199388. doi: 10.1155/2023/6199388. eCollection 2023. J Obes. 2023. PMID: 38026824 Free PMC article.
-
Cardiac-to-adipose axis in metabolic homeostasis and diseases: special instructions from the heart.Cell Biosci. 2023 Sep 4;13(1):161. doi: 10.1186/s13578-023-01097-1. Cell Biosci. 2023. PMID: 37667400 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical